Atypische Neuroleptika werden heute für die Behandlung von Patienten mit schizophrenen Erkrankungen als Therapie der ersten Wahl empfohlen, da sie gegenüber den typischen Neuroleptika deutliche Vorteile hinsichtlich des Wirkungsspektrums und des Nebenwirkungsprofils aufweisen. Dies trifft insbesondere für ersterkrankte Patienten zu, da für diese Patientengruppe im Vergleich zu Mehrfacherkrankten ein höheres Risiko für extrapyramidal-motorische Nebenwirkungen beschrieben wurde. Ob die Vorteile der atypischen Neuroleptika aber auch nachweisbar sind, wenn typische Neuroleptika in niedrigen Dosierungen eingesetzt werden, ist bisher empirisch unzureichend geprüft. Vor diesem Hintergrund wurden im Rahmen einer multizentrischen, doppelblinden, randomisierten klinischen Studie des Kompetenznetz Schizophrenie die Effekte von Risperidon und Haloperidol im Niedrigdosisbereich (Tagesdosen von 2 mg bis maximal 8 mg für beide Medikamente) in der Akutbehandlung ersterkrankter Patienten verglichen.
Summary
The advantages of atypical neuroleptics compared with typical neuroleptics made them to the first choice treatment in schizophrenic disorders. This is especially true for first episode patients because previous studies revealed that these patients show an increased probability for adverse events. However, there is a lack of empirical evidence, whether the advantages of atypical neuroleptics are present also when typical neuroleptics are administered in rather low doses. On this background, the German Research Network on Schizophrenia carried out a multicenter, doubleblind, randomized parallel-group study in patients with first episode schizophrenia. The effects of risperidone and haloperidole are compared withina low dose range (daily doses of2 to 8 mg for both drugs).
2
American Psychiatric Association.
Practice guideline for the treatment of patients with schizophrenia. 2th edition.. Washington DC: American Psychiatric Association; 2004
3
Bottlender R,
Jäger M,
Groll C,
Strauss A,
Möller HJ.
Deficit states in schizophrenia and their association with the length of illness and gender. Eur Arch Psychiatry Clin Neurosci 2001; 251: 272-8.
4
Bottlender R,
Sato T,
Jäger M,
Groll C,
Strauss A,
Möller HJ.
The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur Arch Psychiatry Clin Neurosci 2002; 252: 226-31.
5
Bottlender R,
Sato T,
Jäger M,
Wegener U,
Wittmann J,
Strauss A,
Möller HJ.
The impact of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 2003; 62: 37-44.
7
Emsley R.
Risperidone in the treatment of firstepisode psychotic patients:a double blind multicenter study. Risperidone Working Grou. Schizophr Bull 1999; 25: 721-9.
8
Geddes J,
Freemantle N,
Harrison P,
Bebbington P.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 32: 1371-6.
9
Häfner H,
Maurer K,
Löffler W,
Riecher-Rössler A.
The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-6.
11
Kay SR.
Positive and negative syndromes in schizophrenia: Assessment and research. Clinical and experimental psychiatry monography No. 5. New York, NY: Brunner/Mazel; 1991
12
Klosterkötter J,
Hellmich M,
Steinmeyer EM,
Schultze-Lutter F.
Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-64.
13
Larsen TK,
Friis S,
Haahr U,
Joa I,
Johannessen JO,
Melle I,
Opjordsmoen S,
Simonsen E,
Vaglum P.
Early detection and intervention in first episode schizophrenia: a critical review. Acta Psychiatr Scand 2001; 103: 323-34.
14
Leucht S,
Pitschel-Walz G,
Abraham D,
Kissling W.
Efficacy and extrapyramidal side effects of new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68.
15
Leucht S,
Wahlbeck K,
Hamann J,
Kissling W.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
16
Lieberman JA,
Alvir J,
Woerner M,
Degreet G,
Bilder RM,
Ashtari M,
Bogerts B,
Mayerhoff DI,
Geisler SH,
Loebel a,
Levy DL,
Hinrichsen G,
Szymanski S,
Chakos M,
Koreen A,
Borenstein M,
Kane J.
Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18: 351-71.
17
Lieberman JA,
Koreen AR,
Chakos M,
Sheitman B,
Woerner M,
Alvir J,
Bilder R.
Factors influencing treatment response and outcome of first episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 (Suppl. 09) 5-9.
19
McEvoy JP,
Hogarty GE,
Steingard S.
Optimal dose of neuroleptic in acute schizophrenia a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739-45.
22
Möller HJ.
Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. Eur Arch Psychiatry Clin Neurosci 2005; 255: 190-201.
23
National Institute for Clinical Excellence.
Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London: NICE; 2002
25
Oosthuizen P,
Emsley RA,
Keyter K,
Niehaus DJH,
Koen L.
Duration of untreated psychosis and outcome in first episode psychosis. Perspective from a developing country. Acta Psychiatr Scand 2005; 11: 214-9.
